1
|
Hendrickson BA, McShea C, Ball G, Talbot S. How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci 2024; 58:579-590. [PMID: 38555342 DOI: 10.1007/s43441-024-00634-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 02/15/2024] [Indexed: 04/02/2024]
Abstract
In June 2021, FDA released a Draft Guidance on Sponsor Responsibilities for IND Safety Reporting and cited components of a recommended Safety Surveillance Plan (SSP). To meet the expectations of the 2021 FDA guidance, sponsors should document their plan for aggregate safety assessment. The Drug Information Association-American Statistical Association Interdisciplinary Safety Evaluation scientific working group has proposed an Aggregate Safety Assessment Plan (ASAP) that addresses this recommendation. The 2021 FDA guidance also discusses potential strategies for unblinded review of safety data from ongoing studies by an independent Assessment Entity, which could occur via planned periodic evaluations or "triggered" reviews based on blinded data assessments. The Assessment Entity reviewing unblinded data makes recommendations as to whether the threshold has been met for submission of an aggregate IND safety report. In this paper, we discuss how the ASAP supports IND aggregate safety reporting decisions, including elements to be included in a proposed SSP appendix to the ASAP. In addition, the authors advocate for the benefits of developing a charter (or specific section of the Data Monitoring Committee charter, if applicable) that describes the responsibilities and conduct of the Assessment Entity. With these components in place, study sponsors will meet the objective of having clearly defined processes for the monitoring of clinical trial safety data in aggregate and making IND safety reporting decisions.
Collapse
Affiliation(s)
| | - Cynthia McShea
- Biometrics and Quantitative Sciences, UCB Biosciences, Inc., Morrisville, NC, USA
| | - Greg Ball
- ASAP Process Consulting, Manalapan, NJ, USA
| | | |
Collapse
|
2
|
Gebel M, Renz C, Rodriguez L, Simonetti A, Yang H, Edwards B, Higginson JM, Charpentier N, Colopy M. A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry. Ther Innov Regul Sci 2024; 58:756-765. [PMID: 38649524 DOI: 10.1007/s43441-024-00650-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 03/29/2024] [Indexed: 04/25/2024]
Abstract
BACKGROUND This industry survey was conducted to gain insight into the ways structured Benefit-Risk assessment (sBRA) of medical products is approached across drug or medical device developing companies, including frameworks and methods that are currently used and areas where future work is being planned. METHODS A survey containing 28 questions covering five key areas of sBRA was set-up and shared with representatives from the participating companies. Each company was asked to complete a single survey response including inputs across the company's multidisciplinary key representatives involved in benefit-risk assessment. RESULTS Of the 26 participating companies, 21 (81%) are conducting sBRA. Considering these 21 qualitative frameworks were used by almost every company (19, 90%), while only 12 (57%) have used a quantitative method. Many companies have sBRA training (17, 81%), document templates (16,76%), Standard Operating Procedures (SOPs)/checklists (13, 62%), and /or best practice manuals/examples (12,57%) available. Considering all 26 companies Software tools (15, 58%) and BR planning documents (11,42%) were identified as areas into which many companies intend to put effort. CONCLUSIONS The industry survey confirmed a wide usage of sBRA by many companies involved in research and development. Nevertheless, sBRA is evolving and several future opportunities like the implementation of visualization tools were identified by the representatives of the pharmaceutical companies. Finally, challenges like the cross-functional comprehension of the added value of sBRA are still seen.
Collapse
Affiliation(s)
- Martin Gebel
- Statistics & Data Insights, Bayer AG, Aprather Weg 18a, 42113, Wuppertal, Germany.
| | - Cheryl Renz
- Convene Pharma Consulting, LLC, Greater Chicago Area, USA
| | - Lisa Rodriguez
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Arianna Simonetti
- Center for Devices and Radiological Health, U. S. Food and Drug Administration, Silver Spring, MD, USA
| | - Hong Yang
- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | | | | | | | | |
Collapse
|
3
|
Kieffer ME. Why Oncology Global Safety Teams Should Develop the Safety Section of the Study's Target Product Profile (TPP). Pharmaceut Med 2024; 38:97-108. [PMID: 38411854 DOI: 10.1007/s40290-024-00516-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/05/2024] [Indexed: 02/28/2024]
Abstract
Oncology Global Safety Teams (GSTs) are not universally tasked with the development of the risk section of the products target product profile (TPP). This fact makes little sense since the GST is tasked by the company to identify, analyze, and mitigate a product's risks. The TPP, in essence, establishes boundaries for go/no-go decisions around a product or products in combination treatment. Involvement of the Oncology GST in producing a well-researched and evidenced based TPP safety section allows the team to develop knowledge around the drug(s) studied or added to a study arm. The increased use of umbrella and platform studies for early-phase oncology trials allows an excellent resource for the use of clinical data to estimate the risk of developmental drugs combined to treat a given oncology indication. To shorten time to marketing, companies are including developmental products with novel mechanisms early within their development cycles. Antibody drug conjugates (ADCs) and bi-directional antibodies are a few examples of products combined in arms of a platform or umbrella study early and with only immature clinical data available. This article will share a novel analytical approach for safety teams to develop a well thought-out and defendable safety section to the TPP. Strategies to estimate the risks associated with combination therapies will be brought forward. The advantages of having the safety team involved early in the benefit/risk, go/no-go decisions for a study or the addition of a study arm will be detailed. The early development of a well-documented TPP will enhance chances of a successful product submission.
Collapse
Affiliation(s)
- Michael E Kieffer
- Focused Consulting, Staffing, and Drug Safety (FCSDS), Alexandria, VA, USA.
| |
Collapse
|
4
|
Ball G, Li M, Buchanan J, Hendrickson B, Zink RC, Snapinn S, Herson J. Aggregate IND Safety Reporting for Smaller Companies and Programs. Ther Innov Regul Sci 2024; 58:368-379. [PMID: 38190028 DOI: 10.1007/s43441-023-00605-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2023] [Accepted: 12/01/2023] [Indexed: 01/09/2024]
Abstract
The United States (US) Food and Drug Administration (FDA) Investigational New Drug (IND) Final Rule (US FDA, Final rule: Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans, 2010) applies to all human drugs and biological products being studied under an IND. The Final Rule specifies that a sponsor must file an IND safety report for any Suspected Unexpected Serious Adverse Reaction (SUSAR) of a medicinal product being investigated. To make a proper SUSAR classification, sponsors need to go beyond conventional Data Monitoring Committees (DMCs) with an interdisciplinary effort, using all relevant data (including data outside clinical trials), to make judgments on the possibility of serious adverse events being caused by the study drug-rather than the underlying condition of the patient or a concomitant therapy. Ball et al. (Ball et al. in Ther Innov Regul Sci 55:705-716, 2021) have reported on how the Final Rule has been implemented by large pharmaceutical companies. This paper explores the experiences of small sponsor companies regarding the Final Rule, to understand the current challenges that they have been facing to meet aggregate IND safety reporting requirements.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jay Herson
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| |
Collapse
|
5
|
Hendrickson BA, Agarwal A, Bennett D, Kübler J, McShea C, Tremmel L. Value and Implementation of the Aggregate Safety Assessment Plan. Pharmaceut Med 2023; 37:171-181. [PMID: 37072647 DOI: 10.1007/s40290-023-00470-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/09/2023] [Indexed: 04/20/2023]
Abstract
Aggregate safety assessment involves evaluation of the totality of safety data to characterize the emerging safety profile of a product. The Drug Information Association-American Statistical Association Interdisciplinary Safety Evaluation scientific working group recently published an approach to developing an Aggregate Safety Assessment Plan (ASAP). Creation of an ASAP facilitates a consistent approach to safety data collection and analysis across studies and minimizes important missing data at the time of regulatory submission. A critical aspect of the ASAP is identification of the Safety Topics of Interest (STOI). The STOI, as defined in the ASAP, comprises adverse events (AEs), which have the potential to impact the benefit: risk profile of a product and typically require specialized data collection or analyses. While there are clear benefits to developing an ASAP for a drug development program, multiple concerns may be encountered with implementation. This article uses the examples of two STOIs to demonstrate the benefits and efficiencies gained with implementation of the ASAP in safety planning as well as in optimally characterizing the emerging safety profile of a product.
Collapse
Affiliation(s)
| | | | - Dimitri Bennett
- Takeda Development Center Americas, Inc., Global Evidence and Outcomes, Cambridge, MA, USA
| | - Jürgen Kübler
- QSciCon, Quantitative Scientific Consulting, Marburg, Germany
| | - Cynthia McShea
- UCB Biosciences, Statistical Science and Innovation, Morrisville, NC, USA
| | - Lothar Tremmel
- CSL Behring, Quantitative Clinical Sciences and Reporting, King of Prussia, PA, USA
| |
Collapse
|
6
|
Brock K, Chen C, Ho S, Fuller G, Woolfolk J, McShea C, Penard N. A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials. Pharm Stat 2023; 22:378-395. [PMID: 36510711 DOI: 10.1002/pst.2278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 10/21/2022] [Accepted: 11/19/2022] [Indexed: 12/15/2022]
Abstract
Sponsors have a responsibility to minimise risk to participants in clinical studies through safety monitoring. The FDA Final Rule for IND Safety Reporting requires routine aggregate safety evaluation, including in ongoing blinded studies. We are interested in estimating the probability that the true adverse event rate in the experimental arm exceeds that in the control arm. We developed a Bayesian approach that specifies an informative meta-analytic predictive prior on the event probability in the control arm and an uninformative prior on that in the experimental arm. We combined these priors with a mixture likelihood that considers each patient in the ongoing blinded study may belong to the experimental or control arm. This allowed us to estimate the quantity of interest without unblinding. We evaluated our method by simulation, pairing scenarios that differed only in whether a safety signal was present or missing, and quantifying the ability of our model to discriminate using signal detection theory. Our approach shows benefit. It detects safety signals more reliably with greater sample sizes and for common rather than rare events. Performance does not deteriorate markedly when historical studies exhibit heterogeneous hazards or non-constant hazards. Our method will allow us to monitor safety signals in ongoing blinded studies with the goal of earlier identification and risk mitigation. Our method could be adapted to use informative priors on both arms or predictive covariates where pertinent data exist. We stress that ongoing safety monitoring should involve a multi-disciplinary team where statistical methods are paired with medical judgement.
Collapse
Affiliation(s)
- Kristian Brock
- Centre for Excellence in Statistical Innovation, UCB Pharma, Slough, UK
| | - Chen Chen
- Safety Standards, UCB Pharma, Brussels, Belgium
| | - Shuyen Ho
- Safety Standards, UCB Biosciences, Morrisville, North Carolina, USA
| | | | | | - Cindy McShea
- Safety Standards, UCB Biosciences, Morrisville, North Carolina, USA
| | - Nils Penard
- Safety Standards, UCB France, Colombes, France
| |
Collapse
|
7
|
Waschbusch M, Rodriguez L, Brueckner A, Lee KJ, Li X, Mokliatchouk O, Tremmel L, Yuan SS. Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions. Pharmaceut Med 2022; 36:201-213. [PMID: 35780471 DOI: 10.1007/s40290-022-00435-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2022] [Indexed: 11/24/2022]
Abstract
In the last decade there has been a significant increase in the literature discussing the use of benefit-risk methods in medical product (including devices) development. Government agencies, medical product industry groups, academia, and collaborative consortia have extensively discussed the advantages of structured benefit-risk assessments. However, the abundance of information has not resulted in a consistent way to utilize these findings in medical product development. Guidelines and papers on methods, even though well structured, have not led to a firm consensus on a clear and consistent approach. This paper summarizes the global landscape of benefit-risk considerations for product- or program-level decisions from available literature and regulatory guidance, providing the perspectives of three stakeholder groups-regulators, collaborative groups and consortia, and patients. The paper identifies key themes, potential impact on benefit-risk assessments, and significant future trends.
Collapse
Affiliation(s)
- Max Waschbusch
- Global Clinical Safety and Pharmacovigilance, CSL Behring, King of Prussia, PA, USA.
| | - Lisa Rodriguez
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | | | - Kerry Jo Lee
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - Xuefeng Li
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | | | - Lothar Tremmel
- Quantitative Sciences and Reporting, CSL Behring, King of Prussia, PA, USA
| | - Shuai S Yuan
- Oncology Statistics, GlaxoSmithKline Plc, Upper Province, PA, USA
| |
Collapse
|